search
Back to results

Intracolonic Vancomycin Therapy in Severe C. Diff Colitis

Primary Purpose

Colitis

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Vancomycin
Saline
Sponsored by
William Beaumont Hospitals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colitis focused on measuring Clostridium, Colitis, Intracolonic vancomycin, psuedomembranous colitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • SICU patient
  • positive c. diff toxin assay
  • visualization of pseudomembranes on colonoscopy,
  • able to give consent or have representative to give consent.

Exclusion Criteria:

  • Under age 18
  • pregnant
  • absence of a colon or surgical discontinuity of bowel
  • allergy to vancomycin
  • need for anti-diarrheal medication
  • need for prolonged antibiotics for other cause
  • need for probiotics
  • need for other medications with action against C. diff.
  • need for surgery, colon perforation
  • recent IV IG use
  • toxic megacolon.

Sites / Locations

  • William Beaumont Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Saline

Vancomycin

Arm Description

The saline arm will receive normal saline through the catheter as a placebo.

The vancomycin arm will receive vancomycin solution through the catheter.

Outcomes

Primary Outcome Measures

Resolution of Diarrhea and White Blood Cell Count Elevation
If the patient has resolution of diarrhea, white blood cell count, and abdominal pain, the protocol will be stopped.

Secondary Outcome Measures

Mortality
Death within 30 days of enrollment, in or out of hospital
Need for Colectomy
Partial or complete colectomy performed within 30 days of enrollment

Full Information

First Posted
March 3, 2011
Last Updated
February 8, 2017
Sponsor
William Beaumont Hospitals
search

1. Study Identification

Unique Protocol Identification Number
NCT01346059
Brief Title
Intracolonic Vancomycin Therapy in Severe C. Diff Colitis
Official Title
Intracolonic Vancomycin Therapy in Severe C. Diff Colitis: A Double Blinded Randomized Prospective Trial
Study Type
Interventional

2. Study Status

Record Verification Date
December 2016
Overall Recruitment Status
Terminated
Why Stopped
Technical issues with catheter placement; researcher left institution
Study Start Date
April 2011 (undefined)
Primary Completion Date
February 2012 (Actual)
Study Completion Date
February 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
William Beaumont Hospitals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Clostridium difficile is a bacteria that can infect the colon and cause severe diarrhea in patients after recent antibiotic use. The current standard of care treatment for severe C. diff. consists of oral vancomycin and/or intravenous metronidazole. When treatment is unsuccessful, it can lead to need for removal of the entire colon or even death. In fact, mortality rates in the literature range from 11-37% for C. diff. The most commonly quoted mortality rate is 14% for severe infection. It is believed that the failure of treatment may stem from an adynamic ileus (paralysis of the small bowel). This ileus may prevent the oral vancomycin from reaching the colon and therefore it does not treat the problem. Vancomycin functions by direct contact with the colon. Therefore, if the vancomycin is instilled directly into the colon, it can come into contact with and be its intended target. : The objective of the study is to improve treatment of severe C. diff. colitis . C. diff. infection is defined as severe if there is evidence of ileus accompanied by any one of the following: fever greater than 38.30C, , acidemia, serum albumin less than 2.5, or white blood cell count greater than 14,000.
Detailed Description
Patients in the surgical intensive care unit with severe C. diff. are eligible and if consented will be randomized in a 1:1 ratio to a control group or the treatment group. Each group will undergo a colonoscopy on day one of the study. A 14 French Cook colonic decompression catheter will be placed at that time. This catheter is a 175cm long soft flexible catheter designed to be placed in the colon. Its usual use is to remove air from a colon that is dilated. The catheter is placed into the colon by first placing a guidewire through the colonoscope. The colonoscope is then removed leaving the guidewire in place. The catheter is then thread into the colon over the guidewire. An xray is obtained to confirm the location of the catheter and then the guidewire is removed. The guidewire is a very thin, soft, flexible wire. The patient will not have any undue discomfort secondary to the catheter. The control group will have 250cc of sterile saline solution instilled through the catheter into the colon every 6 hours. The study group will have 250cc of vancomycin solution instilled every 6 hours. The solution will be 2 grams vancomycin dissolved in a 1 liter normal saline irrigation bottle. The catheter will be clamped in both groups after instillation until the next treatment. Of note, both groups will receive the current standard treatment of 500mg IV metronidazole every 8 hours and 250mg oral vancomycin every 6 hours throughout the study. Every day the patients will have a blood draw to check the white blood cell count as is the current practice. The patients will also have a vancomycin trough level checked via blood test. This will occur just prior to the first dosing on treatment day number 3. This will be a blinded lab value as to not unblind the investigators. At resolution Patients will undergo a repeat colonoscopy when there is a decrease of diarrhea (less than 3 stools daily) and a normalized white blood cell count or on day 7 if symptoms persist. The expected length of treatment is approximately 7 days. If there is no improvement at fourteen days, the trial will be stopped for futility. The trial will also be halted if the attending physician determines that the patient needs surgery or if the clinical status of the patient has deteriorated to a point where keeping the patient enrolled will potentially cause harm. Follow-up after completing the trial will consist of phone interviews to screen for recurrence of infection. A weekly phone call will be made for the first three weeks and then two monthly calls will take place after that for a total of three months follow-up. The primary investigator will make these phone calls.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colitis
Keywords
Clostridium, Colitis, Intracolonic vancomycin, psuedomembranous colitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
2 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Saline
Arm Type
Placebo Comparator
Arm Description
The saline arm will receive normal saline through the catheter as a placebo.
Arm Title
Vancomycin
Arm Type
Experimental
Arm Description
The vancomycin arm will receive vancomycin solution through the catheter.
Intervention Type
Drug
Intervention Name(s)
Vancomycin
Other Intervention Name(s)
Vancocin
Intervention Description
Vancomycin solution will be instilled through the colonic catheter every 6 hours. 250cc of solution will be used each time. The solution is 2 grams vancomycin mixed in 1 liter normal saline.
Intervention Type
Drug
Intervention Name(s)
Saline
Other Intervention Name(s)
Normal Saline
Intervention Description
Saline, used as a placebo, will be instilled through the colonic catheter. Every 6 hours, 250cc of saline will be used.
Primary Outcome Measure Information:
Title
Resolution of Diarrhea and White Blood Cell Count Elevation
Description
If the patient has resolution of diarrhea, white blood cell count, and abdominal pain, the protocol will be stopped.
Time Frame
14 days
Secondary Outcome Measure Information:
Title
Mortality
Description
Death within 30 days of enrollment, in or out of hospital
Time Frame
30 day
Title
Need for Colectomy
Description
Partial or complete colectomy performed within 30 days of enrollment
Time Frame
30 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: SICU patient positive c. diff toxin assay visualization of pseudomembranes on colonoscopy, able to give consent or have representative to give consent. Exclusion Criteria: Under age 18 pregnant absence of a colon or surgical discontinuity of bowel allergy to vancomycin need for anti-diarrheal medication need for prolonged antibiotics for other cause need for probiotics need for other medications with action against C. diff. need for surgery, colon perforation recent IV IG use toxic megacolon.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc B Grodsky, MD
Organizational Affiliation
William Beaumont Hospitals
Official's Role
Principal Investigator
Facility Information:
Facility Name
William Beaumont Hospital
City
Royal Oak
State/Province
Michigan
ZIP/Postal Code
48073
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Intracolonic Vancomycin Therapy in Severe C. Diff Colitis

We'll reach out to this number within 24 hrs